Display options
Cite
Bahar A, Kashi Z, Kheradmand M, et al. Prevalence of metabolic syndrome using international diabetes federation, National Cholesterol Education Panel- Adult Treatment Panel III and Iranian criteria: results of Tabari cohort study. J Diabetes Metab Disord. 2020;19(1):205-211doi: 10.1007/s40200-020-00492-6.
Bahar, A., Kashi, Z., Kheradmand, M., Hedayatizadeh-Omran, A., Moradinazar, M., Ramezani, F., Afshari, M., & Moosazadeh, M. (2020). Prevalence of metabolic syndrome using international diabetes federation, National Cholesterol Education Panel- Adult Treatment Panel III and Iranian criteria: results of Tabari cohort study. Journal of diabetes and metabolic disorders, 19(1), 205-211. https://doi.org/10.1007/s40200-020-00492-6
Bahar, Adeleh, et al. "Prevalence of metabolic syndrome using international diabetes federation, National Cholesterol Education Panel- Adult Treatment Panel III and Iranian criteria: results of Tabari cohort study." Journal of diabetes and metabolic disorders vol. 19,1 (2020): 205-211. doi: https://doi.org/10.1007/s40200-020-00492-6
Bahar A, Kashi Z, Kheradmand M, Hedayatizadeh-Omran A, Moradinazar M, Ramezani F, Afshari M, Moosazadeh M. Prevalence of metabolic syndrome using international diabetes federation, National Cholesterol Education Panel- Adult Treatment Panel III and Iranian criteria: results of Tabari cohort study. J Diabetes Metab Disord. 2020 Jan 17;19(1):205-211. doi: 10.1007/s40200-020-00492-6. eCollection 2020 Jun. PMID: 32550169; PMCID: PMC7270474.
Copy Download .nbib Format: NLM
Share it on

J Diabetes Metab Disord. 2020 Jan 17;19(1):205-211. doi: 10.1007/s40200-020-00492-6. eCollection 2020 Jun.

Prevalence of metabolic syndrome using international diabetes federation, National Cholesterol Education Panel- Adult Treatment Panel III and Iranian criteria: results of Tabari cohort study.

Journal of diabetes and metabolic disorders

Adeleh Bahar, Zahra Kashi, Motahareh Kheradmand, Akbar Hedayatizadeh-Omran, Mahdi Moradinazar, Fatemeh Ramezani, Mahdi Afshari, Mahmood Moosazadeh

Affiliations

  1. Diabetes research center, Mazandaran University of medical sciences, Sari, Iran.
  2. Health Sciences Research center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran.
  3. Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
  4. Research Center for Environmental Determinants of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  5. Department of Community Medicine, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran.

PMID: 32550169 PMCID: PMC7270474 DOI: 10.1007/s40200-020-00492-6

Abstract

BACKGROUND: Metabolic syndrome is defined by co-incidence of multiple metabolic disorders such as central obesity, high triglycerides, low HDL, hyperglycemia and high blood pressure, which increases the risk of cardiovascular disease and diabetes. The aim of this study was to estimate the prevalence of metabolic syndrome using Adult Treatment Panel III (ATP-III), International Diabetes Federation (IDF) and Iranian criteria in large-scaled population based cohort study and to determine the concordance between these criteria.

METHODS: In the present study all information collected in Tabari cohort study(TCS) were utilized. These information were collected using a structural questionnaire and taking blood samples from all the participants. Blood pressure and anthropometric indices were measured for all participants by trained practitioners. Categorical variables were compared using chi-square test. In addition, the quantitative variables were compared between the two the groups using independent t-test. Kappa coefficient was estimated to show the agreement between the results of the three criteria.

RESULTS: The prevalences of Metabolic syndrome were 41.10%(CI 95%:40.10-42.02), 44.60%(CI 95%:43.61-45.54), and 30.80% (CI 95%:29.89-31.69) based on ATPIII, international IDF and IDF Iranian criteria respectively. The Kappa agreement coefficients between Iranian IDF with ATPIII definition and international IDF were estimated as 61.80% and 71.20% in the total population respectively.

CONCLUSION: Kappa coefficient showed that the Iranian IDF had a good agreement with International IDF and an intermediate agreement with the ATP-III. Considering more emphasis of international and Iranian IDF on waist circumference (WC), a better agreement between these two criteria is plausible. Regarding the high prevalence of abdominal obesity among Iranian population, applying these criteria to identify high risk persons might be helpful.

© Springer Nature Switzerland AG 2020.

Keywords: ATP-III; Metabolic syndrome; international IDF; Tabari cohort study

Conflict of interest statement

Conflict of interestNone declared.

References

  1. Exp Diabetes Res. 2009;2009:136501 - PubMed
  2. Int J Public Health. 2012 Jun;57(3):543-50 - PubMed
  3. Lancet. 2005 Sep 24-30;366(9491):1059-62 - PubMed
  4. Arch Iran Med. 2010 Sep;13(5):426-8 - PubMed
  5. Diabetes Res Clin Pract. 2008 Oct;82(1):104-7 - PubMed
  6. Electron Physician. 2017 Oct 25;9(10):5402-5418 - PubMed
  7. Trends Cardiovasc Med. 2016 May;26(4):364-73 - PubMed
  8. Iran J Public Health. 2017 Apr;46(4):456-467 - PubMed
  9. Diabetes Metab Syndr. 2014 Jul-Sep;8(3):170-6 - PubMed
  10. Biomed Res Int. 2013;2013:760963 - PubMed
  11. Ethn Dis. 2016 Jan 21;26(1):99-106 - PubMed
  12. Diabetes Res Clin Pract. 2007 Aug;77(2):251-7 - PubMed
  13. Nutrition. 2005 Sep;21(9):969-76 - PubMed
  14. Cardiol Res Pract. 2014;2014:943162 - PubMed
  15. Obes Rev. 2015 Jan;16(1):1-12 - PubMed
  16. Arch Iran Med. 2017 Nov 01;20(11):691-695 - PubMed
  17. Am J Epidemiol. 2018 Apr 1;187(4):647-655 - PubMed
  18. Prev Med Rep. 2017 Jul 19;7:211-215 - PubMed
  19. Arq Bras Cardiol. 2009 Aug;93(2):85-91 - PubMed
  20. Diabetes Care. 2005 Oct;28(10):2588-9 - PubMed
  21. Circulation. 2005 Oct 25;112(17):2735-52 - PubMed
  22. Iran Red Crescent Med J. 2015 Dec 27;17(12):e24723 - PubMed
  23. Metab Syndr Relat Disord. 2009 Jun;7(3):221-9 - PubMed
  24. Acta Diabetol. 2006 Nov;43(3):84-6 - PubMed

Publication Types